Nanjing Pharmaceutical (600713.SH): Guangzhou Pharmaceuticals, a subsidiary of Baiyunshan, plans to acquire 145 million shares of the company

Zhtng Cijng APP News, Nanjing Pharmaceutical (600713.SH) announced that the company has signed a "Strategic Investment Agreement" with Baiyunshan (600332.SH) and Guangzhou Pharmaceutical Second Phase Fund Equity Investment Partnership Enterprise (Limited Partnership) (referred to as "Guangzhou Pharmaceutical Second Phase Fund"). Baiyunshan's subsidiary Guangzhou Pharmaceutical Second Phase Fund intends to invest through the agreement to acquire all the 145 million shares held by the company's current second largest shareholder, Alliance Healthcare Asia Pacific Limited, representing 11.04% of the total share capital of the company as of the date of the agreement.